2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172836S
    GLP-1 receptor agonist 17-d3 3074098-20-4 98%
    GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.
    GLP-1 receptor agonist 17-d3
  • HY-17356S1
    Fenofibrate-d4 1092484-57-5 98%
    Fenofibrate-d4 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-d4
  • HY-17369BS
    Tirofiban-d9 1332075-40-7 98%
    Tirofiban-d9 is deuterium labeled Tirofiban.
    Tirofiban-d9
  • HY-17402S3
    Nisoldipine-d3 98%
    Nisoldipine-d3 is deuterated labeled Nisoldipine (HY-17402). Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.
    Nisoldipine-d3
  • HY-17412AS
    Minocycline-d6 1036070-10-6 98%
    Minocycline-d6 is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d6
  • HY-17436S1
    Clevidipine-d7 98%
    Clevidipine-d7 is the deuterium labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.
    Clevidipine-d7
  • HY-17436S3
    (R)-Clevidipine-13C,d3 98%
    (R)-Clevidipine-13C,d3 is the deuterium and 13C labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.
    (R)-Clevidipine-13C,d3
  • HY-17436S4
    Clevidipine-15N,d10 98%
    Clevidipine-15N,d10 is 15N and deuterated labeled Clevidipine (HY-17436). Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H)=-40 mV ).
    Clevidipine-15N,d10
  • HY-17464S1
    Cilostazol-d4 1215541-47-1 98%
    Cilostazol-d4 is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.
    Cilostazol-d4
  • HY-17503BR
    Metoprolol tartrate (Standard) 56392-17-7 98%
    Metoprolol (tartrate) (Standard) is the analytical standard of Metoprolol (tartrate). This product is intended for research and analytical applications. Metoprolol tartrate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol tartrate shows anti-inflammation, antitumor and anti-angiogenic properties.
    Metoprolol tartrate (Standard)
  • HY-17503BS
    Metoprolol-d6 tartrate 98%
    Metoprolol-d6 (tartrate) is the deuterium labeled Metoprolol tartrate. Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.
    Metoprolol-d6 tartrate
  • HY-17504AS
    Rosuvastatin-d3 1133429-16-9 98%
    Rosuvastatin-d3 (ZD 4522-d3) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals.
    Rosuvastatin-d3
  • HY-176303S
    Apolipoprotein E3, U-15N
    Apolipoprotein E3, U-15N is the 15N-labeled Apolipoprotein E3.
    Apolipoprotein E3, U-15N
  • HY-176312S
    Apolipoprotein A1, U-15N
    Apolipoprotein A1, U-15N is the 15N-labeled Apolipoprotein A1.
    Apolipoprotein A1, U-15N
  • HY-176313S
    Carboxypeptidase B2, Arg-13C6,15N4, Lys-13C6,15N2
    Carboxypeptidase B2, Arg-13C6,15N4, Lys-13C6,15N2 is the 13C-labeled and 15N-labeled Carboxypeptidase B2.
    Carboxypeptidase B2, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-176316S
    Troponin I, U-15N
    Troponin I, U-15N is the 15N-labeled Troponin I.
    Troponin I, U-15N
  • HY-177148A
    G256 dihydrochloride 134867-96-2
    G256 (Compound 1) (dihydrochloride) is an amidinohydrazone. G256 (dihydrochloride) can also be considered as a Schiff’s base of aminoguanidine. G256 (dihydrochloride) exhibits antiarrhythmic activity. G256 (dihydrochloride) is the reduced form of NOH-G256 by microsomal enzyme preparation from rabbit and rat liver homogenates in the presence of NADPH and NADH.
    G256 dihydrochloride
  • HY-18100AR
    PRE-084 hydrochloride (Standard) 75136-54-8
    PRE-084 (hydrochloride) (Standard) is the analytical standard of PRE-084 (hydrochloride). This product is intended for research and analytical applications. PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway.
    PRE-084 hydrochloride (Standard)
  • HY-18204S3
    (Rac)-Valsartan-d9 98%
    (Rac)-Valsartan-d9 is deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
    (Rac)-Valsartan-d9
  • HY-18252S1
    Avanafil-13C5,15N,d2 98%
    Avanafil-13C5,15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil-13C5,15N,d2
Cat. No. Product Name / Synonyms Application Reactivity